Lilly beats Novo in another study Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 26 February, 2026

Rethink what's possible for mature products — Download the playbook sponsored by Cencora

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

spotlight Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news OrbiMed jumps to number one on the top 100 list of biotech venture investors Sarepta CEO Doug Ingram to step down, ending controversial tenure at Duchenne biotech Lilly’s GLP-1 pill beats Novo’s in diabetes trial, but has more side effects Japanese conglomerate Asahi Kasei to buy German antiviral biotech Aicuris for $920M

Mar 03 12:00 pm ET Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

endpoints pharma Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug States sue Kennedy over US childhood vaccine overhaul Gilead, Merck plan to debut new daily HIV pills Charles River sells its CDMO and European discovery businesses

in case you missed it 1. Novo Nordisk teams with Langer-founded biotech for oral obesity drugs 2. GSK to buy pulmonary hypertension biotech for $950M 3. Richard Pops to retire as Alkermes CEO, capping 35-year tenure 4. Polymer nanoparticle startup raises $60M for mRNA diabetes therapy 5. News Briefing Accent axes a cancer study; Werewolf considers its options 6. The age of animal experiments is waning. Where will science go next?